Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | CDKN2B |
| Gene Name: | CDKN2B |
| Protein Full Name: | Cyclin-dependent kinase 4 inhibitor B |
| Alias: | CDKN2B; CDN2B; MTS2; Multiple tumor suppressor 2; P14-INK4b |
| Mass (Da): | 14722 |
| Number AA: | 138 |
| UniProt ID: | P42772 |
| Locus ID: | 1030 |
| COSMIC ID: | CDKN2B |
| Gene location on chromosome: | 9p21 |
| Cancer protein type: | TSP |
| Effect of cancer mutation on protein: | LOSS |
| Effect of active protein on cancer: | INHIBITS |
| Number of cancer specimens: | 21053 |
| Percent of cancer specimens with mutations: | 0.1 |
| Gene undergoes hypermethylation: | Promoter methylation was also detected in 37% of patients diagnosed with glioblastoma and it correlated with shorter survival. Hypermethylation is found in up to 60% of CMML cases and correlates with a more aggressive form of disease. hypermethylation of |
| Normal role description: | CDKN2B functions as a protein-kinase inhibitor, with exclusive specificity to CDK4/6 -- both oncoproteins; thus this gene can be considered a tumour suppressor gene. CDKN2B is frequently epigenetically silenced in leukemias, myelodysplastic syndromes and myeloproliferative diseases by mechanisms involving aberrant DNA methylation and/or histone modifications. |
| Commentary on involvement of protein in cancer: | Interacts strongly with CDK4 and CDK6. Potent inhibitor. Potential effector of TGF-beta induced cell cycle arrest. |